Nitroxoline showed anticancer activity in breast, bladder, pancreatic, and prostate cancer (as well as myeloma or gliomas) by activating cell apoptosis, arresting cell cycle, and suppressing angiogenesis through MetAP2 activity inhibition. This evidence concerns the gene METAP2 and glioma.